600645 中源协和
交易中 09-14 09:35:05
资讯
新帖
简况
中源协和（600645）2026年中报简析：净利润同比增长5.67%，盈利能力上升
证券之星 · 08-29
中源协和（600645）2026年中报简析：净利润同比增长5.67%，盈利能力上升
图解中源协和中报：第二季度单季净利润同比增长23.75%
证券之星 · 08-27
图解中源协和中报：第二季度单季净利润同比增长23.75%
中源协和：VUM02/03共11个适应症已获临床试验批准
证券之星 · 08-05
中源协和：VUM02/03共11个适应症已获临床试验批准
中源协和：尚未达成对公司业务产生重大影响的BD合作
证券之星 · 08-05
中源协和：尚未达成对公司业务产生重大影响的BD合作
股市必读：中源协和新发布《东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司2025年年度报告的信息披露监管问询函回复的核查意见》
证券之星 · 08-03
股市必读：中源协和新发布《东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司2025年年度报告的信息披露监管问询函回复的核查意见》
每周股票复盘：中源协和（600645）2025年营收14.55亿元
证券之星 · 08-02
每周股票复盘：中源协和（600645）2025年营收14.55亿元
中源协和（600645）披露2025年年报问询函核查意见，国家干细胞基地三期项目进度为0.34%，XX月XX日股价下跌0.54%
证券之星 · 07-30
中源协和（600645）披露2025年年报问询函核查意见，国家干细胞基地三期项目进度为0.34%，XX月XX日股价下跌0.54%
股市必读：中源协和（600645）7月17日收盘跌6.54%，主力净流出2067.6万元
证券之星 · 07-20
股市必读：中源协和（600645）7月17日收盘跌6.54%，主力净流出2067.6万元
每周股票复盘：中源协和（600645）VUM02注射液I期多剂首例给药完成
证券之星 · 07-19
每周股票复盘：中源协和（600645）VUM02注射液I期多剂首例给药完成
中源协和最新公告：VUM02注射液I期临床试验首例受试者完成入组给药
证券之星 · 07-17
中源协和最新公告：VUM02注射液I期临床试验首例受试者完成入组给药
股市必读：中源协和（600645）7月10日董秘有最新回复
证券之星 · 07-13
股市必读：中源协和（600645）7月10日董秘有最新回复
中源协和：目前还在沟通中
证券之星 · 07-10
中源协和：目前还在沟通中
股市必读：中源协和（600645）7月7日收盘跌6.33%，主力净流入685.4万元
证券之星 · 07-08
股市必读：中源协和（600645）7月7日收盘跌6.33%，主力净流入685.4万元
每周股票复盘：中源协和（600645）使用1.2亿闲置募资购买结构性存款
证券之星 · 07-05
每周股票复盘：中源协和（600645）使用1.2亿闲置募资购买结构性存款
每周股票复盘：中源协和（600645）将召开2025年度业绩说明会
证券之星 · 06-20
每周股票复盘：中源协和（600645）将召开2025年度业绩说明会
中源协和（600645）披露2025年年度股东会决议公告，5月19日股价上涨0.9%
证券之星 · 05-19
中源协和（600645）披露2025年年度股东会决议公告，5月19日股价上涨0.9%
中源协和（600645）披露归还临时补充流动资金的募集资金公告，5月18日股价下跌1.81%
证券之星 · 05-18
中源协和（600645）披露归还临时补充流动资金的募集资金公告，5月18日股价下跌1.81%
每周股票复盘：中源协和（600645）将召开2025年年度股东会
证券之星 · 05-17
每周股票复盘：中源协和（600645）将召开2025年年度股东会
中源协和（600645）披露2025年年度股东会召开提示性公告，5月13日股价上涨0.12%
证券之星 · 05-13
中源协和（600645）披露2025年年度股东会召开提示性公告，5月13日股价上涨0.12%
中源协和（600645）披露关于计提资产减值损失的公告，4月27日股价下跌2.07%
证券之星 · 04-27
中源协和（600645）披露关于计提资产减值损失的公告，4月27日股价下跌2.07%
公司概况
公司名称：
中源协和细胞基因工程股份有限公司
所属行业：
研究和试验发展
上市日期：
1993-05-04
主营业务：
中源协和细胞基因工程股份有限公司的主营业务是细胞检测制备及存储，体外诊断原料、体外诊断试剂和器械的研产销，生物基因、蛋白、抗体等科研试剂产品，以及基因检测服务，干细胞、免疫细胞临床应用的研发及转化等。公司的主要产品是细胞检测制备及存储、基因检测、科研试剂、检测试剂。
发行价格：
50.00
{"stockData":{"symbol":"600645","market":"SH","secType":"STK","nameCN":"中源协和","latestPrice":17.83,"timestamp":1789349705000,"preClose":17.78,"halted":0,"volume":271655,"delay":0,"changeRate":0.0028,"floatShares":468000000,"shares":468000000,"eps":0.2503,"marketStatus":"交易中","change":0.05,"latestTime":"09-14 09:35:05","open":17.72,"high":17.85,"low":17.69,"amount":4825500,"amplitude":0.009,"askPrice":17.82,"askSize":2,"bidPrice":17.81,"bidSize":31,"shortable":0,"etf":0,"ttmEps":0.2503,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789356600000},"marketStatusCode":2,"adr":0,"adjPreClose":17.78,"symbolType":"stock","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":19.56,"lowLimit":16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":467948890,"isCdr":false,"pbRate":2.22,"roa":"--","peRate":71.234519,"roe":"1.64%","epsLYR":0.25,"committee":-0.181818,"marketValue":8344000000,"turnoverRate":0.0006,"status":0,"floatMarketCap":8340000000},"requestUrl":"/m/hq/s/600645/wiki","defaultTab":"wiki","newsList":[{"id":"2663328016","title":"中源协和（600645）2026年中报简析：净利润同比增长5.67%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663328016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663328016?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:04","pubTimestamp":1787954647,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期中源协和发布2026年中报。截至本报告期末，公司营业总收入6.59亿元，同比下降7.96%，归母净利润6104.84万元，同比上升5.67%。按单季度数据看，第二季度营业总收入3.42亿元，同比下降6.44%，第二季度归母净利润3680.35万元，同比上升23.75%。本报告期中源协和盈利能力上升，毛利率同比增幅3.29%，净利率同比增幅23.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900010381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600645"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701398","title":"图解中源协和中报：第二季度单季净利润同比增长23.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701398","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662701398?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:15","pubTimestamp":1787829339,"startTime":"0","endTime":"0","summary":"证券之星消息，中源协和2026年中报显示，上半年度公司主营收入6.59亿元，同比下降7.96%；归母净利润6104.84万元，同比上升5.67%；扣非净利润4484.73万元，同比下降16.78%；其中2026年第二季度，公司单季度主营收入3.42亿元，同比下降6.44%；单季度归母净利润3680.35万元，同比上升23.75%；单季度扣非净利润2769.81万元，同比上升8.64%；负债率28.45%，投资收益-255.69万元，财务费用-1019.02万元，毛利率70.95%。财报数据概要请见下图:本文数据来源于中源协和2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700045412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600645"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657480885","title":"中源协和：VUM02/03共11个适应症已获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657480885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657480885?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:24","pubTimestamp":1785925451,"startTime":"0","endTime":"0","summary":"证券之星消息，中源协和08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司VUM02干细胞注射液已获批新冠治疗Ⅱ/lll期临床试验与重症/危重症肺炎Ⅱ/lll期临床试验，请问目前有没有患者入组？公司全资子公司武汉光谷药业自主研发的人脐带间充质干/ 基质细胞产品VUM02/03共11个适应症已获临床试验批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500034489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","600645","BK0188","BK0042","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548759","title":"中源协和：尚未达成对公司业务产生重大影响的BD合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657548759?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:24","pubTimestamp":1785925450,"startTime":"0","endTime":"0","summary":"对于将优势产品向海外药企授权等BD合作模式，公司持积极和开放态度，已建立了相关团队，会结合国内外行业情况、公司经营及资源情况，审慎考虑相关方向。目前尚未达成对公司业务产生重大影响的BD合作，如有达到信息披露要求的重大进展，公司将严格按照相关法律法规及信息披露规则及时履行披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500034488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0216","600645","BK0042","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656234393","title":"股市必读：中源协和新发布《东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司2025年年度报告的信息披露监管问询函回复的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656234393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656234393?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:56","pubTimestamp":1785696971,"startTime":"0","endTime":"0","summary":"公司公告汇总中源协和细胞基因工程股份有限公司关于公司2025年年度报告的信息披露监管问询函的回复公告公司就上交所关于2025年年度报告的信息披露监管问询函作出回复，涉及主营业务、应收账款、其他应收款、商誉减值及募投项目进展等事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600645","BK0042","BK0276","BK0028","BK0183","601198","BK0239","BK0012","BK0009","BK0046","BK0188","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656333319","title":"每周股票复盘：中源协和（600645）2025年营收14.55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656333319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656333319?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:59","pubTimestamp":1785610748,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，中源协和报收于18.77元，较上周的17.8元上涨5.45%。本周，中源协和7月30日盘中最高价报19.13元。公司2025年实现营业收入14.55亿元，其中海外收入2.99亿元，同比下降16.51%；国内业务收入11.20亿元，同比下降5.35%。检测试剂业务收入8.58亿元，毛利率68.08%，因病理检测试剂占比上升带动毛利提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600645"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655806361","title":"中源协和（600645）披露2025年年报问询函核查意见，国家干细胞基地三期项目进度为0.34%，XX月XX日股价下跌0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655806361?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:29","pubTimestamp":1785421754,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，中源协和报收于18.58元，较前一交易日下跌0.54%，最新总市值为86.94亿元。该股当日开盘18.6元，最高19.13元，最低18.39元，成交额达1.49亿元，换手率为1.71%。近日，东兴证券股份有限公司发布《关于中源协和细胞基因工程股份有限公司2025年年度报告的信息披露监管问询函回复的核查意见》。公司已披露相关研发项目进展及投入情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600645","BK0042","BK0188","BK0239","BK0046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652162252","title":"股市必读：中源协和（600645）7月17日收盘跌6.54%，主力净流出2067.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652162252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652162252?lang=zh_cn&edition=full","pubTime":"2026-07-20 01:08","pubTimestamp":1784480892,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，中源协和报收于17.85元，下跌6.54%，换手率3.08%，成交量14.41万手，成交额2.63亿元。交易信息汇总股价提醒7月17日中源协和收盘报17.85元，跌6.54%，当日成交2.63亿元。前10个交易日主力资金累计净流入426.74万元，股价累计下跌6.54%；融资余额累计增加127.38万元，融券余量累计增加2.18万股。资金流向7月17日主力资金净流出2067.6万元；游资资金净流入675.54万元；散户资金净流入1392.06万元。截至2026年5月，项目累计研发投入830.89万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000000562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600645","BK0216","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237054","title":"每周股票复盘：中源协和（600645）VUM02注射液I期多剂首例给药完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237054","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237054?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:02","pubTimestamp":1784397735,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，中源协和报收于17.85元，较上周的18.37元下跌2.83%。本周，中源协和7月16日盘中最高价报19.37元。本周关注点公司公告汇总：VUM02注射液I期多次给药首例受试者完成入组给药公司公告汇总中源协和全资子公司武汉光谷中源药业有限公司收到国家药监局核准签发的VUM02注射液临床试验批准通知书，拟用于激素治疗失败的II度至IV度急性移植物抗宿主病。VUM02注射液为自主研发的人脐带源间充质干细胞制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0216","600645","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409934","title":"中源协和最新公告：VUM02注射液I期临床试验首例受试者完成入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409934","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652409934?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:05","pubTimestamp":1784279121,"startTime":"0","endTime":"0","summary":"中源协和(600645.SH)公告称，公司全资子公司武汉光谷中源药业有限公司自主研发的VUM02注射液，用于激素治疗失败的II度至IV度急性移植物抗宿主病的I/II期临床试验，其I期多次给药首例受试者已于2026年7月17日完成入组给药。截至2026年5月，该项目累计研发投入为830.89万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","600645","BK0046","BK0188","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651657141","title":"股市必读：中源协和（600645）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651657141","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651657141?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:34","pubTimestamp":1783877650,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，中源协和报收于18.37元，上涨4.08%，换手率3.32%，成交量15.51万手，成交额2.82亿元。董秘最新回复投资者： 6月29日公司高管在业绩交流会上介绍：关于年报审计披露监管工作函的自查回复与相关部门正在沟通中，请问目前是否已经完成？目前还在沟通中。交易信息汇总资金流向7月10日主力资金净流出837.12万元；游资资金净流出394.77万元；散户资金净流入1231.9万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","600645","BK0042","BK0216","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650899111","title":"中源协和：目前还在沟通中","url":"https://stock-news.laohu8.com/highlight/detail?id=2650899111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650899111?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:48","pubTimestamp":1783676887,"startTime":"0","endTime":"0","summary":"证券之星消息，中源协和(600645)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问：6月29日公司高管在业绩交流会上介绍：关于年报审计披露监管工作函的自查回复与相关部门正在沟通中，请问目前是否已经完成？中源协和回复：投资者，您好！感谢您的关注。目前还在沟通中。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000032321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600645","BK0216","BK0042","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934792","title":"股市必读：中源协和（600645）7月7日收盘跌6.33%，主力净流入685.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934792","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649934792?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:19","pubTimestamp":1783448350,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，中源协和报收于18.21元，下跌6.33%，换手率4.08%，成交量19.09万手，成交额3.55亿元。交易信息汇总：前10个交易日主力资金累计净流入3698.8万元，同期股价累计下跌6.33%。交易信息汇总：7月7日主力资金净流入685.4万元，游资净流入232.86万元，散户净流出918.26万元。交易信息汇总股价提醒7月7日中源协和收盘报18.21元，跌6.33%，当日成交3.55亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","BK0239","BK0216","600645","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649269412","title":"每周股票复盘：中源协和（600645）使用1.2亿闲置募资购买结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2649269412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649269412?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:34","pubTimestamp":1783190052,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，中源协和报收于18.55元，较上周的16.74元上涨10.81%。本周，中源协和7月3日盘中最高价报18.76元。中源协和当前最新总市值86.8亿元，在医疗器械板块市值排名36/129，在两市A股市值排名2179/5203。本周关注点公司公告汇总：中源协和使用1.2亿元暂时闲置募集资金购买华夏银行结构性存款产品，期限89天，预计年化收益率1.00%-1.81%。此前用于现金管理的1.2亿元募集资金已全部赎回，获得收益20.25万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","BK0239","BK0216","600645","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063010","title":"每周股票复盘：中源协和（600645）将召开2025年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063010","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644063010?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:37","pubTimestamp":1781894230,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，中源协和报收于18.35元，较上周的18.72元下跌1.98%。本周，中源协和6月15日盘中最高价报18.88元。中源协和当前最新总市值85.87亿元，在医疗器械板块市值排名34/129，在两市A股市值排名2210/5206。本周关注点公司公告汇总：中源协和将于2026年6月29日召开2025年度业绩说明会。公司公告汇总中源协和细胞基因工程股份有限公司将于2026年6月29日15:00-16:30通过中国证券报中证网以网络视频播放和网络文字互动方式召开2025年度业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0042","BK0216","BK0188","600645"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636837198","title":"中源协和（600645）披露2025年年度股东会决议公告，5月19日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636837198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636837198?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:10","pubTimestamp":1779185440,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，中源协和报收于22.48元，较前一交易日上涨0.9%，最新总市值为105.19亿元。中源协和细胞基因工程股份有限公司于2026年5月18日召开2025年年度股东会，审议通过了《公司2025年度董事会工作报告》《公司2025年度利润分配预案》等议案。出席会议股东所持表决权股份占公司总股本的23.5768%，所有议案均获通过，无否决议案。北京国枫律师事务所对本次会议出具法律意见书，认为会议合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0216","BK0042","600645","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636402944","title":"中源协和（600645）披露归还临时补充流动资金的募集资金公告，5月18日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636402944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636402944?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:30","pubTimestamp":1779096637,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，中源协和报收于22.28元，较前一交易日下跌1.81%，最新总市值为104.26亿元。近日，中源协和细胞基因工程股份有限公司发布《关于归还临时补充流动资金的募集资金的公告》。截至2026年5月15日，公司已将临时补充流动资金的18,000万元全部归还至募集资金专项账户，并通知了保荐机构及保荐代表人，归还金额为18,000万元，尚未归还金额为0，使用期限未超过12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800026291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600645","BK0216","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061834","title":"每周股票复盘：中源协和（600645）将召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636061834?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:36","pubTimestamp":1778952973,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，中源协和报收于22.69元，较上周的24.85元下跌8.69%。本周，中源协和5月11日盘中最高价报25.25元。公司公告汇总中源协和细胞基因工程股份有限公司将于2026年5月18日召开2025年年度股东会，会议采取现场投票与网络投票相结合方式。中源协和细胞基因工程股份有限公司于2025年5月20日召开董事会及监事会会议，审议通过使用不超过1.8亿元闲置募集资金暂时补充流动资金，使用期限不超过12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600645","BK0216","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786877","title":"中源协和（600645）披露2025年年度股东会召开提示性公告，5月13日股价上涨0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635786877?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:52","pubTimestamp":1778669554,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，中源协和报收于24.35元，较前一交易日上涨0.12%，最新总市值为113.95亿元。该股当日开盘24.4元，最高24.55元，最低24.0元，成交额达1.83亿元，换手率为1.61%。中源协和细胞基因工程股份有限公司于近日发布《关于召开2025年年度股东会的提示性公告》。公告显示，公司定于2026年5月18日召开2025年年度股东会，会议采取现场投票与网络投票相结合方式。股权登记日为2026年5月11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300035999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600645","BK0042","BK0188","BK0239","BK0046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630679283","title":"中源协和（600645）披露关于计提资产减值损失的公告，4月27日股价下跌2.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630679283","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630679283?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:23","pubTimestamp":1777285413,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，中源协和报收于26.53元，较前一交易日下跌2.07%，最新总市值为124.15亿元。中源协和细胞基因工程股份有限公司于2026年4月25日发布《关于计提资产减值损失的公告》。公告显示，公司于2026年4月24日召开董事会，审议通过计提资产减值损失的议案。公司2025年度合计计提减值损失38,889,136.75元，收回或转回已计提减值损失1,805,457.76元，转销或核销4,772,523.85元。其中应收账款计提23,348,983.30元，存货跌价损失计提15,210,879.08元。本次计提减少公司2025年度利润37,083,678.99元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","600645","BK0216","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789349710210,"stockEarnings":[{"period":"1week","weight":-0.0451},{"period":"1month","weight":-0.1056},{"period":"3month","weight":-0.0502},{"period":"6month","weight":-0.3991},{"period":"1year","weight":-0.2947},{"period":"ytd","weight":-0.2944}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中源协和细胞基因工程股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"36689人(较上一季度减少7.55%)","perCapita":"12749股","listingDate":"1993-05-04","address":"天津市西青区滨海高新区华苑产业区梅苑路12号【A】座二层房屋","registeredCapital":"46794万元","survey":" 中源协和细胞基因工程股份有限公司的主营业务是细胞检测制备及存储，体外诊断原料、体外诊断试剂和器械的研产销，生物基因、蛋白、抗体等科研试剂产品，以及基因检测服务，干细胞、免疫细胞临床应用的研发及转化等。公司的主要产品是细胞检测制备及存储、基因检测、科研试剂、检测试剂。","listedPrice":50},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中源协和(600645)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中源协和(600645)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中源协和,600645,中源协和股票,中源协和股票老虎,中源协和股票老虎国际,中源协和行情,中源协和股票行情,中源协和股价,中源协和股市,中源协和股票价格,中源协和股票交易,中源协和股票购买,中源协和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中源协和(600645)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中源协和(600645)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}